Ball Brian, Zeidan Amer, Gore Steven D, Prebet Thomas
a Department of Medicine (Hematology) , Yale School of Medicine , New Haven , CT , USA.
Leuk Lymphoma. 2017 May;58(5):1022-1036. doi: 10.1080/10428194.2016.1228927. Epub 2016 Sep 21.
The hypomethylating agents (HMA) azacitidine and decitabine are both approved by the FDA for the treatment of myelodysplastic syndromes (MDS). Although heralded as a significant advancement, HMA lead to responses in less than half of patients and for those that respond most will relapse. As such, there is a crucial need to improve frontline therapy approaches. One promising strategy involves combining azacitidine or decitabine with investigational or existing therapies with the goal of achieving synergistic activity and better patient outcomes. The purpose of this paper is to critically review the efficacy and safety of reported HMA-based combination regimens in patients with higher-risk MDS.
低甲基化药物（HMA）阿扎胞苷和地西他滨均已获美国食品药品监督管理局（FDA）批准用于治疗骨髓增生异常综合征（MDS）。尽管被誉为一项重大进展，但HMA治疗的患者缓解率不到一半，而且大多数缓解的患者会复发。因此，迫切需要改进一线治疗方法。一种有前景的策略是将阿扎胞苷或地西他滨与研究性或现有疗法联合使用，以期实现协同活性并改善患者预后。本文旨在严格审查已报道的基于HMA的联合治疗方案在高危MDS患者中的疗效和安全性。
